Emergence of resistance to β-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections

L. C. Preheim, R. G. Penn, C. C. Sanders, Richard V. Goering, D. K. Giger

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

In four patients with Pseudomonas aeruginosa infections, the infecting strain developed resistance to moxalactam during therapy with this drug. In addition, P. aeruginosa isolates from two of these four patients showed increased resistance to aminoglycosides. Isolates from a third patient acquired cross-resistance to other antipseudomonal β-lactams. In three of the cases, disk susceptibility tests failed to detect the resistance that was demonstrated in broth dilution assays. Isolate identities were confirmed by serotyping. No new plasmids were found by agarose gel electrophoresis. The mechanisms for this resistance did not involve enzymatic antibiotic degradation. These findings suggest that currently available expanded-spectrum cephalosporin derivatives should probably not be used alone for most serious infections due to P. aeruginosa. They also suggest that strains with multiple antibiotic resistance may become more prevalent in hospitals if these drugs are used extensively.

Original languageEnglish
Pages (from-to)1037-1041
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume22
Issue number6
StatePublished - 1982
Externally publishedYes

Fingerprint

Moxalactam
Pseudomonas Infections
Lactams
Aminoglycosides
Pseudomonas aeruginosa
Anti-Bacterial Agents
Serotyping
Agar Gel Electrophoresis
Cephalosporins
Microbial Drug Resistance
Plasmids
Therapeutics
Drug Therapy
Infection
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Emergence of resistance to β-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections. / Preheim, L. C.; Penn, R. G.; Sanders, C. C.; Goering, Richard V.; Giger, D. K.

In: Antimicrobial Agents and Chemotherapy, Vol. 22, No. 6, 1982, p. 1037-1041.

Research output: Contribution to journalArticle

@article{d05285de7ea042f2ac88a7a24dcd150f,
title = "Emergence of resistance to β-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections",
abstract = "In four patients with Pseudomonas aeruginosa infections, the infecting strain developed resistance to moxalactam during therapy with this drug. In addition, P. aeruginosa isolates from two of these four patients showed increased resistance to aminoglycosides. Isolates from a third patient acquired cross-resistance to other antipseudomonal β-lactams. In three of the cases, disk susceptibility tests failed to detect the resistance that was demonstrated in broth dilution assays. Isolate identities were confirmed by serotyping. No new plasmids were found by agarose gel electrophoresis. The mechanisms for this resistance did not involve enzymatic antibiotic degradation. These findings suggest that currently available expanded-spectrum cephalosporin derivatives should probably not be used alone for most serious infections due to P. aeruginosa. They also suggest that strains with multiple antibiotic resistance may become more prevalent in hospitals if these drugs are used extensively.",
author = "Preheim, {L. C.} and Penn, {R. G.} and Sanders, {C. C.} and Goering, {Richard V.} and Giger, {D. K.}",
year = "1982",
language = "English",
volume = "22",
pages = "1037--1041",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Emergence of resistance to β-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections

AU - Preheim, L. C.

AU - Penn, R. G.

AU - Sanders, C. C.

AU - Goering, Richard V.

AU - Giger, D. K.

PY - 1982

Y1 - 1982

N2 - In four patients with Pseudomonas aeruginosa infections, the infecting strain developed resistance to moxalactam during therapy with this drug. In addition, P. aeruginosa isolates from two of these four patients showed increased resistance to aminoglycosides. Isolates from a third patient acquired cross-resistance to other antipseudomonal β-lactams. In three of the cases, disk susceptibility tests failed to detect the resistance that was demonstrated in broth dilution assays. Isolate identities were confirmed by serotyping. No new plasmids were found by agarose gel electrophoresis. The mechanisms for this resistance did not involve enzymatic antibiotic degradation. These findings suggest that currently available expanded-spectrum cephalosporin derivatives should probably not be used alone for most serious infections due to P. aeruginosa. They also suggest that strains with multiple antibiotic resistance may become more prevalent in hospitals if these drugs are used extensively.

AB - In four patients with Pseudomonas aeruginosa infections, the infecting strain developed resistance to moxalactam during therapy with this drug. In addition, P. aeruginosa isolates from two of these four patients showed increased resistance to aminoglycosides. Isolates from a third patient acquired cross-resistance to other antipseudomonal β-lactams. In three of the cases, disk susceptibility tests failed to detect the resistance that was demonstrated in broth dilution assays. Isolate identities were confirmed by serotyping. No new plasmids were found by agarose gel electrophoresis. The mechanisms for this resistance did not involve enzymatic antibiotic degradation. These findings suggest that currently available expanded-spectrum cephalosporin derivatives should probably not be used alone for most serious infections due to P. aeruginosa. They also suggest that strains with multiple antibiotic resistance may become more prevalent in hospitals if these drugs are used extensively.

UR - http://www.scopus.com/inward/record.url?scp=0020456610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020456610&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 1037

EP - 1041

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -